SAGIMET BIOSCIENCES INC. - SERIES A COMMON STOCK

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

22 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

27 مارس 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

25 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

25 مارس 2024 06:15:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

29 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

25 يناير 2024 20:58:03 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

23 يناير 2024 17:45:51 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

22 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

04 ديسمبر 2023 08:00:01 بحسب Nasdaq GlobeNewswire